Shots:

• Onconova to get clinical- regulatory and sales-based milestones up to $30.4M and royalties on sales.  Specialised to receive exclusive rights to commercialize rigosertib in Australia and New Zealand
• The collaboration is focusing on the results of P-III INSPIRE study (NCT02562443) assessing Rigosertib IV + Best Supportive Care vs Physician's Choice plus Best Supportive Care in ratio (2:1) with its 1EP as OS for patients with Myelodysplastic Syndromes (MDS)
• Rigosertib is a P-III candidate- enables blocking of cellular signaling by targeting RAS effector pathways and is evaluated in P-III as monothx & P-II in combination with azacitidine in 2L higher-risk MDS patients & 1L refractory higher-risk MDS patients respectively

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance